全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:M. Thomas , P. Sadjadian , J. Kollmeier ...
来源:[J].Investigational New Drugs(IF 3.498), 2017, Vol.35 (3), pp.345-358Springer
摘要:Introduction BTH1677, a 1,3–1,6 beta-glucan immunomodulator, stimulates a coordinated anti-cancer immune response in combination with anti-tumor antibody therapies. This phase II study explored the efficacy, pharmacokinetics (PK), and safety of BTH1677 combined with cetuxima...
作者:Monica Mita , Siqing Fu , Sarina Anne Piha-Paul ...
来源:[J].Investigational New Drugs(IF 3.498), 2017, Vol.35 (5), pp.616-626Springer
摘要:Background Dual inhibition of activated MAPK and mTOR signaling pathways may enhance the antitumor efficacy of the MEK 1/2 inhibitor pimasertib and the mTOR inhibitor temsirolimus given in combination. Methods In this phase I study, patients with refractory advanced solid tu...
作者:C.M. Nijenhuis , L. Lucas , H. Rosing ...
来源:[J].Investigational New Drugs(IF 3.498), 2017, Vol.35 (4), pp.478-490Springer
摘要:Background Vosaroxin is a first-in-class anticancer quinolone derivative that is being investigated for patients with relapsed or refractory acute myeloid leukemia (AML). The primary objective of this study was to quantitatively determine the pharmacokinetics of vosaroxin an...
作者:Jennifer R. Diamond , Barbara Goff , Martin D. Forster ...
来源:[J].Investigational New Drugs(IF 3.498), 2017, Vol.35 (5), pp.627-633Springer
摘要:Background This multicenter, open-label, phase Ib study was designed to assess the safety, pharmacokinetics and preliminary efficacy of ME-344, a mitochondrial inhibitor, administered in combination with the topoisomerase I inhibitor, topotecan, in patients with previously treate...
作者:Antonio Jimeno , Manish R. Sharma , Sergio Szyldergemajn ...
来源:[J].Investigational New Drugs(IF 3.498), 2017, Vol.35 (4), pp.471-477Springer
摘要:Background Lurbinectedin administered as a 1-h intravenous infusion every 3 weeks induces neutropenia, with the nadir usually occurring during the second week. This phase I study evaluated an alternative lurbinectedin dosing schedule consisting of a 1-h infusion on days 1 and 8 e...
作者:Chongchong Wang , Li Cheng
来源:[J].Investigational New Drugs(IF 3.498), 2017, Vol.35 (5), pp.655-661Springer
摘要:Gankyrin is an oncoprotein that plays a central role in the development of cancer. Although researchers have increasingly focused on the relationships of gankyrin with carcinogenesis, metastasis and prognosis of different cancers, the molecular mechanisms are still unclear. In re...
作者:Lillian M. Smyth , Kelsey R. Monson , Komal Jhaveri ...
来源:[J].Investigational New Drugs(IF 3.498), 2017, Vol.35 (6), pp.742-750Springer
摘要:Purpose We previously reported the phase I dose escalation study of buparlisib, a pan-class 1A PI3K inhibitor, combined with platinum/taxane-based chemotherapy in patients with advanced solid tumors. The combination was well tolerated and promising preliminary efficacy was o...
作者:Chii Chii Chew , Salby Ng , Yun Lee Chee ...
来源:[J].Investigational New Drugs(IF 3.498), 2017, Vol.35 (4), pp.399-411Springer
摘要:Coadministration of diclofenac and sunitinib, tyrosine kinase inhibitor, led to sex-divergent pharmacokinetic drug-drug interaction outcomes. Male and female mice were administered 60 mg/kg PO sunitinib alone (control groups) or with 30 mg/kg PO diclofenac. Sunitinib concent...
作者:Hisato Kawakami , Junko Tanizaki , Kaoru Tanaka ...
来源:[J].Investigational New Drugs(IF 3.498), 2017, Vol.35 (4), pp.529-536Springer
摘要:Background Nivolumab demonstrates promising efficacy for the treatment of non-small cell lung cancer and other malignancies. The clinical benefit of nivolumab, however, may be hampered by specific immune-related adverse events (irAEs), and little is known regarding nivolumab-rela...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×